OBJECTIVE: To explore the role of alpha-synuclein (αSyn) oligomers and neurofilament light chain (NFL) in cerebrospinal fluid (CSF) as markers of early multiple system atrophy (MSA) and to contrast findings with Lewy body synucleinopathies. METHODS: In a discovery cohort of well-characterized early MSA patients (n = 24) and matched healthy controls (CON, n = 14), we utilized enzyme-linked immunosorbent assay to measure NFL and protein misfolding cyclic amplification (PMCA) to detect αSyn oligomers in CSF. We confirmed findings in a separate prospectively enrolled cohort of patients with early MSA (n = 38), Parkinson disease (PD, n = 16), and dementia with Lewy bodies (DLB, n = 13), and CON subjects (n = 15). RESULTS: In the discovery cohort, NFL was markedly elevated in MSA patients, with perfect separation from CON. αSyn-PMCA was nonreactive in all CON, whereas all MSA samples were positive. In the confirmatory cohort, NFL again perfectly separated MSA from CON, and was significantly lower in PD and DLB compared to MSA. PMCA was again nonreactive in all CON, and positive in all but 2 MSA cases. All PD and all but 2 DLB samples were also positive for αSyn aggregates but with markedly different reaction kinetics from MSA; aggregation occurred later, but maximum fluorescence was higher, allowing for perfect separation of reactive samples between MSA and Lewy body synucleinopathies. INTERPRETATION: NFL and αSyn oligomers in CSF faithfully differentiate early MSA not only from CON but also from Lewy body synucleinopathies. The findings support the role of these markers as diagnostic biomarkers, and have important implications for understanding pathophysiologic mechanisms underlying the synucleinopathies. ANN NEUROL 2020;88:503-512.
OBJECTIVE: To explore the role of alpha-synuclein (αSyn) oligomers and neurofilament light chain (NFL) in cerebrospinal fluid (CSF) as markers of early multiple system atrophy (MSA) and to contrast findings with Lewy body synucleinopathies. METHODS: In a discovery cohort of well-characterized early MSA patients (n = 24) and matched healthy controls (CON, n = 14), we utilized enzyme-linked immunosorbent assay to measure NFL and protein misfolding cyclic amplification (PMCA) to detect αSyn oligomers in CSF. We confirmed findings in a separate prospectively enrolled cohort of patients with early MSA (n = 38), Parkinson disease (PD, n = 16), and dementia with Lewy bodies (DLB, n = 13), and CON subjects (n = 15). RESULTS: In the discovery cohort, NFL was markedly elevated in MSA patients, with perfect separation from CON. αSyn-PMCA was nonreactive in all CON, whereas all MSA samples were positive. In the confirmatory cohort, NFL again perfectly separated MSA from CON, and was significantly lower in PD and DLB compared to MSA. PMCA was again nonreactive in all CON, and positive in all but 2 MSA cases. All PD and all but 2 DLB samples were also positive for αSyn aggregates but with markedly different reaction kinetics from MSA; aggregation occurred later, but maximum fluorescence was higher, allowing for perfect separation of reactive samples between MSA and Lewy body synucleinopathies. INTERPRETATION:NFL and αSyn oligomers in CSF faithfully differentiate early MSA not only from CON but also from Lewy body synucleinopathies. The findings support the role of these markers as diagnostic biomarkers, and have important implications for understanding pathophysiologic mechanisms underlying the synucleinopathies. ANN NEUROL 2020;88:503-512.
Authors: Phillip A Low; David Robertson; Sid Gilman; Horacio Kaufmann; Wolfgang Singer; Italo Biaggioni; Roy Freeman; Susan Perlman; Robert A Hauser; William Cheshire; Stephanie Lessig; Steven Vernino; Jay Mandrekar; William D Dupont; Thomas Chelimsky; Wendy R Galpern Journal: Lancet Neurol Date: 2014-02-05 Impact factor: 44.182
Authors: Juan J Figueroa; Wolfgang Singer; Ajay Parsaik; Eduardo E Benarroch; J Eric Ahlskog; Robert D Fealey; Joseph E Parisi; Paola Sandroni; Jay Mandrekar; Valeria Iodice; Phillip A Low; James H Bower Journal: Mov Disord Date: 2014-06-07 Impact factor: 10.338
Authors: T Tokuda; M M Qureshi; M T Ardah; S Varghese; S A S Shehab; T Kasai; N Ishigami; A Tamaoka; M Nakagawa; O M A El-Agnaf Journal: Neurology Date: 2010-10-20 Impact factor: 9.910
Authors: Johannes Levin; Sylvia Maaß; Madeleine Schuberth; Armin Giese; Wolfgang H Oertel; Werner Poewe; Claudia Trenkwalder; Gregor K Wenning; Ulrich Mansmann; Martin Südmeyer; Karla Eggert; Brit Mollenhauer; Axel Lipp; Matthias Löhle; Joseph Classen; Alexander Münchau; Jan Kassubek; Florin Gandor; Daniela Berg; Silvia Egert-Schwender; Cornelia Eberhardt; Friedemann Paul; Kai Bötzel; Birgit Ertl-Wagner; Hans-Jürgen Huppertz; Ingrid Ricard; Günter U Höglinger Journal: Lancet Neurol Date: 2019-07-02 Impact factor: 44.182
Authors: Min Shi; Joshua Bradner; Aneeka M Hancock; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Un Jung Kang; Kevin C Cain; Yu Wang; Jan Aasly; David Goldstein; Jing Zhang Journal: Ann Neurol Date: 2011-03-11 Impact factor: 10.422
Authors: Valeria Iodice; Axel Lipp; J Eric Ahlskog; Paola Sandroni; Robert D Fealey; Joseph E Parisi; Joseph Y Matsumoto; Eduardo E Benarroch; Kurt Kimpinski; Wolfgang Singer; Tonette L Gehrking; Jade A Gehrking; David M Sletten; Ann M Schmeichel; James H Bower; Sid Gilman; Juan Figueroa; Phillip A Low Journal: J Neurol Neurosurg Psychiatry Date: 2012-01-06 Impact factor: 10.154
Authors: Amanda L Woerman; Jan Stöhr; Atsushi Aoyagi; Ryan Rampersaud; Zuzana Krejciova; Joel C Watts; Takao Ohyama; Smita Patel; Kartika Widjaja; Abby Oehler; David W Sanders; Marc I Diamond; William W Seeley; Lefkos T Middleton; Steve M Gentleman; Daniel A Mordes; Thomas C Südhof; Kurt Giles; Stanley B Prusiner Journal: Proc Natl Acad Sci U S A Date: 2015-08-18 Impact factor: 11.205
Authors: Hans-Jürgen Huppertz; Leona Möller; Martin Südmeyer; Rüdiger Hilker; Elke Hattingen; Karl Egger; Florian Amtage; Gesine Respondek; Maria Stamelou; Alfons Schnitzler; Elmar H Pinkhardt; Wolfgang H Oertel; Susanne Knake; Jan Kassubek; Günter U Höglinger Journal: Mov Disord Date: 2016-10 Impact factor: 10.338
Authors: Wolfgang Singer; Allan B Dietz; Anita D Zeller; Tonette L Gehrking; James D Schmelzer; Ann M Schmeichel; Jade A Gehrking; Mariana D Suarez; David M Sletten; Karla V Minota Pacheco; Elizabeth A Coon; Paola Sandroni; Eduardo E Benarroch; Robert D Fealey; Joseph Y Matsumoto; James H Bower; Anhar Hassan; Andrew McKeon; Anthony J Windebank; Jay N Mandrekar; Phillip A Low Journal: Neurology Date: 2019-05-31 Impact factor: 11.800
Authors: Moriah R Arnold; David G Coughlin; Barbara H Brumbach; Denis S Smirnov; Luis Concha-Marambio; Carly M Farris; Yihua Ma; Yongya Kim; Edward N Wilson; Jeffrey A Kaye; Annie Hiniker; Randy L Woltjer; Doug R Galasko; Joseph F Quinn Journal: Ann Neurol Date: 2022-07-29 Impact factor: 11.274
Authors: Iva Stankovic; Alessandra Fanciulli; Vladimir S Kostic; Florian Krismer; Wassilios G Meissner; Jose Alberto Palma; Jalesh N Panicker; Klaus Seppi; Gregor K Wenning Journal: Mov Disord Clin Pract Date: 2021-03-10